Drug
Sparc1102 I
Sparc1102 I: highest development phase Phase 2, developed by Sun Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sun Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPARC1102 I NCT01320553 | Phase 2 | Allergic Conjunctivitis |
Latest
No recent events.
Follow Sparc1102 I on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.